ABOS on Nasdaq
Acumen Pharmaceuticals, Inc.
In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or AßOs, which are globular assemblies of the amyloid-beta, or Aß, peptide that are distinct from Aß monomers and amyloid plaques.”3 It is headquartered in Newton, Massachusetts.1 Its shares trade on Nasdaq under the symbol ABOS.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerABOS on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersNewton, Massachusetts1
- Incorporated inDE2
- Business address1210-1220 Washington Street, Suite 210, Newton, Ma 024652
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Alzheimer’s disease is currently estimated to affect approximately seven million people in the United States and approximately 55 million people worldwide and was the sixth-leading cause of death among individuals aged 65 and older in 2022 in the United States. Due to the aging population, patient populations in the United States impacted by AD are expected to grow to approximately 13 million people by 2050 without effective preventative measures or safe and effective disease-modifying treatments. By 2050, healthcare costs for AD in the United States…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $104.9M | $93.8M |
| General and administrative | $18.9M | $20.2M |
| Total operating expenses | $123.8M | $114.0M |
| Loss from operations | -$123.8M | -$114.0M |
| Interest income | $7.4M | $14.3M |
| Interest expense | -$4.2M | -$4.1M |
| Change in fair value of embedded derivatives | -$460.0K | $1.6M |
| Other expense, net | -$266.0K | -$151.0K |
| Total other income | $2.5M | $11.7M |
| Net loss | -$121.3M | -$102.3M |
| Unrealized gain (loss) on marketable securities | $131.0K | -$360.0K |
| Comprehensive loss | -$121.2M | -$102.7M |
| Net loss per common share, basic (in dollars per share) | -$2.00 | -$1.71 |
| Net loss per common share, diluted (in dollars per share) | -$2.00 | -$1.71 |
| Weighted-average shares outstanding, basic (in shares) | 60.6M shares | 60.0M shares |
| Weighted-average shares outstanding diluted (in shares) | 60.6M shares | 60.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $54.0M | $35.6M | |
| Marketable securities, short-term | $62.9M | $135.9M | |
| Prepaid expenses and other current assets | $5.4M | $6.7M | |
| Total current assets | $122.3M | $178.3M | |
| Marketable securities, long-term | $0 | $60.0M | |
| Restricted cash | $231.0K | $232.0K | |
| Other assets, long-term | $350.0K | $486.0K | |
| Total assets | $122.8M | $239.0M | |
| Accounts payable | $554.0K | $5.6M | |
| Accrued clinical trial expenses | $10.6M | $15.3M | |
| Accrued expenses and other current liabilities | $10.1M | $6.6M | |
| Debt, short-term | $8.8M | $0 | |
| Total current liabilities | $30.0M | $27.6M | |
| Debt, long-term | $22.4M | $29.4M | |
| Other liabilities, long-term | $0 | $150.0K | |
| Total liabilities | $52.4M | $57.2M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $6.0K | $6.0K | |
| Additional paid-in capital | $516.8M | $507.0M | |
| Accumulated deficit | -$446.5M | -$325.1M | |
| Accumulated other comprehensive income (loss) | $83.0K | -$48.0K | |
| Total stockholders equity | $70.4M | $181.8M | $267.0M |
| Total liabilities and stockholders equity | $122.8M | $239.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 60.6M shares | 60.1M shares | |
| Common stock, shares outstanding (in shares) | 60.6M shares | 60.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $54.0M | $35.6M | |
| Marketable securities, short-term | $62.9M | $135.9M | |
| Prepaid expenses and other current assets | $5.4M | $6.7M | |
| Total current assets | $122.3M | $178.3M | |
| Marketable securities, long-term | $0 | $60.0M | |
| Restricted cash | $231.0K | $232.0K | |
| Other assets, long-term | $350.0K | $486.0K | |
| Total assets | $122.8M | $239.0M | |
| Accounts payable | $554.0K | $5.6M | |
| Accrued clinical trial expenses | $10.6M | $15.3M | |
| Accrued expenses and other current liabilities | $10.1M | $6.6M | |
| Debt, short-term | $8.8M | $0 | |
| Total current liabilities | $30.0M | $27.6M | |
| Debt, long-term | $22.4M | $29.4M | |
| Other liabilities, long-term | $0 | $150.0K | |
| Total liabilities | $52.4M | $57.2M | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024; 60,575,369 and 60,094,083 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $6.0K | $6.0K | |
| Additional paid-in capital | $516.8M | $507.0M | |
| Accumulated deficit | -$446.5M | -$325.1M | |
| Accumulated other comprehensive income (loss) | $83.0K | -$48.0K | |
| Total stockholders equity | $70.4M | $181.8M | $267.0M |
| Total liabilities and stockholders equity | $122.8M | $239.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 300.0M shares | 300.0M shares | |
| Common stock, shares issued (in shares) | 60.6M shares | 60.1M shares | |
| Common stock, shares outstanding (in shares) | 60.6M shares | 60.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$121.3M | -$102.3M |
| Depreciation | $58.0K | $63.0K |
| Stock-based compensation expense | $9.9M | $9.6M |
| Amortization of premiums and accretion of discounts on marketable securities, net | -$809.0K | -$5.0M |
| Change in fair value of embedded derivatives | $460.0K | -$1.6M |
| Amortization of right-of-use asset | $126.0K | $115.0K |
| Realized gain on marketable securities | -$59.0K | -$97.0K |
| Noncash interest expense | $1.3M | $1.1M |
| Other noncash expense | $0 | $232.0K |
| Prepaid expenses and other current assets | $1.4M | -$3.7M |
| Other long-term assets | $40.0K | $74.0K |
| Accounts payable | -$5.1M | $4.3M |
| Accrued clinical trial expenses | -$4.7M | $11.0M |
| Accrued expenses and other liabilities | $3.3M | $32.0K |
| Finance lease liability | $0 | -$23.0K |
| Net cash used in operating activities | -$115.5M | -$86.2M |
| Purchases of marketable securities | -$38.1M | -$170.7M |
| Proceeds from maturities and sales of marketable securities | $172.1M | $218.8M |
| Purchases of property and equipment | -$88.0K | -$16.0K |
| Net cash provided by investing activities | $133.9M | $48.0M |
| Proceeds from issuance of common stock, net of issuance costs | $0 | $7.9M |
| Proceeds from exercise of stock options | $39.0K | $0 |
| Payment for financing lease | $0 | -$739.0K |
| Payments for deferred offering costs | $0 | -$230.0K |
| Repurchase of common shares to pay employee withholding taxes | -$73.0K | -$41.0K |
| Net cash (used in) provided by financing activities | -$34.0K | $6.9M |
| Net change in cash and cash equivalents and restricted cash | $18.4M | -$31.3M |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $2.9M | $3.0M |
No quarter-by-quarter statement was filed.
Corporate structure
Acumen Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Acumen Pharmaceuticals, Inc.
- James B. Murray Jr. Filed SCHEDULE 13G on Acumen Pharmaceuticals, Inc., latest Apr 7, 2026 (3 filings since Feb 14, 2022)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13D/A on Acumen Pharmaceuticals, Inc., latest Mar 17, 2026 (3 filings since Jul 25, 2023)
- Franklin Templeton Investments Filed SCHEDULE 13G/A on Acumen Pharmaceuticals, Inc., latest Nov 4, 2025 (2 filings since Feb 6, 2024)
- Sands Capital Alternatives, LLC Filed SCHEDULE 13G/A on Acumen Pharmaceuticals, Inc., latest Aug 13, 2025 (2 filings since Feb 14, 2023)
- Deep Track Capital, LP Filed SC 13G/A on Acumen Pharmaceuticals, Inc., latest Feb 14, 2024 (3 filings since Jan 27, 2022)
- Paul B. Manning Filed SC 13G/A on Acumen Pharmaceuticals, Inc., latest Feb 14, 2023 (2 filings since Feb 15, 2022)
- BlackRock Filed SC 13G/A on Acumen Pharmaceuticals, Inc., latest Oct 7, 2022 (2 filings since Feb 4, 2022)
- Molly G. Hardie Filed SC 13G on Acumen Pharmaceuticals, Inc., latest Feb 16, 2022
- Acumen Pharmaceuticals, Inc. Newton, Massachusetts
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Acumen Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $200.0K8 Dec 31, 2025 | $100.0K8 Dec 31, 2024 | +100.0% |
| Property and equipment, net | $103.0K8 Dec 31, 2025 | $73.0K8 Dec 31, 2024 | +41.1% |
| Operating-lease assets (leased space) | $140.0K8 Dec 31, 2025 | $266.0K8 Dec 31, 2024 | −47.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $54.0M8 Dec 31, 2025 | $35.6M8 Dec 31, 2024 | +51.5% |
| Marketable securities, current | $62.9M8 Dec 31, 2025 | $135.9M8 Dec 31, 2024 | −53.7% |
| Marketable securities, non-current | $08 Dec 31, 2025 | $60.0M8 Dec 31, 2024 | −100.0% |
| Debt securities available for sale | $195.9M8 Dec 31, 2024 | $239.2M7 Dec 31, 2023 | −18.1% |
Properties, in its own words
Our corporate headquarters are located in Newton, Massachusetts, where we lease approximately 3,758 square feet of office space pursuant to a 38-month lease, which commenced in October 2023. We also lease a small office in Towson, Maryland pursuant to a 12-month lease, which commenced in January 2026, and a small office in Charlottesville, Virginia, which is leased on a month-to-month basis. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.
Item 2 of the 10-K filed Mar 26, 2026.3
Leadership
Who has led Acumen Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
2025
- PresidentJames J. Doherty Feb 1, 2024 to now11
- Chief financial officerMatt Zuga Jun 30, 2021 to now12
- Chief operating officerRussell Barton Jun 30, 2021 to now13
Board members and other officers (13)
- Chief Regulatory OfficerAmy Schacterle Nov 6, 2024 to now14
- Chief Medical OfficerEric Siemers Jun 30, 2021 to now15
- Board memberGeorge Golumbeski Nov 10, 2025 to now16
- Board memberDerrell Porter Jan 4, 2023 to now17
- Board memberKimberlee C. Drapkin Apr 4, 2022 to now18
- Board memberJeffrey L. Ives Jun 30, 2021 to now19
- Board memberJeffrey Sevigny Jun 30, 2021 to Jun 17, 202220
- Board memberLaura Stoppel Jun 30, 2021 to now21
- Board memberNathan B. Fountain Jun 30, 2021 to now22
- Board memberPeter Kolchinsky Jun 30, 2021 to now23
- Board memberRajeev M. Shah Jun 30, 2021 to now23
- Board memberSean Stalfort Jun 30, 2021 to now24
- General counselDerek M. Meisner Sep 7, 2022 to now25
Timeline
- Sep 16, 20268-K Regulation FD disclosure26
- Aug 12, 20268-K Results of operations; Regulation FD disclosure27
- Jun 16, 20268-K Regulation FD disclosure; Other events28
- Jun 3, 20268-K Shareholder vote29
- May 12, 20268-K Results of operations; Regulation FD disclosure30
- Mar 26, 20268-K Results of operations; Regulation FD disclosure31
- Mar 16, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure32
- Jan 12, 20268-K Regulation FD disclosure33
- Nov 12, 20258-K Results of operations; Regulation FD disclosure34
- Nov 10, 20258-K Executive or director change; Regulation FD disclosure35
- Aug 12, 20258-K Results of operations; Regulation FD disclosure36
- Jul 15, 20258-K Entered a material agreement; Regulation FD disclosure37
Calendar
Coming up
- Oct 26, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.44) a share, on Nov 12, 2025.38
When it reported results
- Aug 12, 2026Reported quarterly or annual results27
- May 12, 2026Reported quarterly or annual results30
- Mar 26, 2026Reported quarterly or annual results31
- Nov 12, 2025Reported quarterly or annual results34
- Aug 12, 2025Reported quarterly or annual results36
- May 13, 2025Reported quarterly or annual results39
- Mar 27, 2025Reported quarterly or annual results40
- Nov 12, 2024Reported quarterly or annual results41
Drug trials and FDA: coming up
- Oct 2026Phase 2 trial readout expected Phase 2 trial of sabirnetug in Alzheimer Disease: primary completion expected Oct 2026 (ClinicalTrials.gov NCT06335173).42
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
300 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 112 insider forms, 18 large holders, 99 other. The latest 20:
- Sep 16, 20268-K EDGAR
- Aug 12, 2026S-8 EDGAR
- Aug 12, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Jun 17, 2026144 EDGAR
- Jun 17, 20264 EDGAR
- Jun 16, 2026144 EDGAR
- Jun 16, 20268-K EDGAR
- Jun 15, 2026144 EDGAR
- Jun 10, 20264 EDGAR
- Jun 9, 2026144 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 3, 20268-K EDGAR
The 300 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
62 open-market trades by officers, directors and large owners since October 2021: 1 buys and 61 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Porter DerrellDirector | Sale | 13,040 | $2.33 | $30.4K | Form 4 |
| Jun 16, 2026 | Porter DerrellDirector | Sale | 12,800 | $2.33 | $29.8K | Form 4 |
| Jun 15, 2026 | Porter DerrellDirector | Sale | 6,460 | $2.35 | $15.2K | Form 4 |
| Jun 9, 2026 | Fountain Nathan BDirector | Sale | 6,400 | $2.23 | $14.3K | Form 4 |
| Mar 6, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 2,090 | $3.26 | $6.8K | Form 4 |
| Feb 27, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 9,406 | $3.01 | $28.3K | Form 4 |
| Jan 28, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 2,671 | $3.00 | $8.0K | Form 4 |
| Jan 26, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 15,085 | $3.00 | $45.3K | Form 4 |
| Jan 23, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 5,633 | $1.90 | $10.7K | Form 4 |
| Jan 22, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 1,054 | $1.84 | $1.9K | Form 4 |
| Jan 22, 2026 | Siemers EricChief Medical Officer | Sale | 895 | $1.82 | $1.6K | Form 4 |
| Jan 22, 2026 | Zuga MattCFO & Chief Business Officer | Sale | 1,687 | $1.86 | $3.1K | Form 4 |
| Jan 22, 2026 | OConnell Daniel JosephChief Executive Officer | Sale | 2,689 | $1.88 | $5.1K | Form 4 |
| Jan 22, 2026 | Barton RussellChief Operating Officer | Sale | 462 | $1.84 | $850 | Form 4 |
| Jan 21, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 2,247 | $1.81 | $4.1K | Form 4 |
| Jan 21, 2026 | Siemers EricChief Medical Officer | Sale | 2,331 | $1.80 | $4.2K | Form 4 |
| Jan 21, 2026 | Zuga MattCFO & Chief Business Officer | Sale | 2,473 | $1.81 | $4.5K | Form 4 |
| Jan 21, 2026 | OConnell Daniel JosephChief Executive Officer | Sale | 9,346 | $1.81 | $16.9K | Form 4 |
| Jan 21, 2026 | Barton RussellChief Operating Officer | Sale | 2,315 | $1.81 | $4.2K | Form 4 |
| Jan 12, 2026 | Meisner Derek MChief Legal Officer & Corp Sec | Sale | 8,548 | $1.71 | $14.6K | Form 4 |
All 62 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- James B. Murray Jr.SCHEDULE 13G, 3 filings Feb 14, 2022 to Apr 7, 202643
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A, 3 filings Jul 25, 2023 to Mar 17, 202644
- Franklin Templeton InvestmentsSCHEDULE 13G/A, 2 filings Feb 6, 2024 to Nov 4, 202545
- Sands Capital Alternatives, LLCSCHEDULE 13G/A, 2 filings Feb 14, 2023 to Aug 13, 202546
- Deep Track Capital, LPSC 13G/A, 3 filings Jan 27, 2022 to Feb 14, 202447
- Paul B. ManningSC 13G/A, 2 filings Feb 15, 2022 to Feb 14, 202348
- BlackRockSC 13G/A, 2 filings Feb 4, 2022 to Oct 7, 202249
- Molly G. HardieSC 13G, 1 filing Feb 16, 202250
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | DanielO’Connell | $646.4K | $1.9M51 | |
| 2025 | Jim Doherty | $520.0K | $1.0M51 | |
| 2025 | Matthew Zuga | 60 | $487.0K | $948.8K51 |
| 2024 | Chief Executive Officer | $621.5K | $4.8M51 | |
| 2024 | President and Chief DevelopmentOfficer | $458.3K | $2.2M51 | |
| 2024 | Chief Financial Officer andChief Business Officer | $468.3K | $1.7M51 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 95. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20,992,669 | $56.1M | 0.5% | No change |
| Sands Capital Alternatives, LLC | 3,720,105 | $9.9M | 1.6% | No change |
| BlackRock, Inc. | 2,490,115 | $6.6M | 0.0% | +2,311,789 |
| Alyeska Investment Group, L.P. | 2,454,754 | $6.6M | 0.0% | No change |
| Franklin Resources Inc | 2,305,096 | $6.2M | 0.0% | No change |
| ADAR1 Capital Management, LLC | 2,111,334 | $5.6M | 0.3% | −45,000 |
| Vanguard Capital Management LLC | 1,672,072 | $4.5M | 0.0% | +165,795 |
| Knollwood Investment Advisory, LLC | 1,628,510 | $4.3M | 0.4% | No change |
| Geode Capital Management, LLC | 1,141,858 | $3.0M | 0.0% | +725,620 |
| Ikarian Capital, LLC | 1,053,797 | $2.8M | 0.5% | No change |
| Hudson Bay Capital Management LP | 955,000 | $2.5M | 0.0% | −13,940 |
| Pathstone Holdings, LLC | 859,110 | $2.3M | 0.0% | No change |
| Renaissance Technologies LLC | 675,025 | $1.8M | 0.0% | +201,079 |
| Two Sigma Investments, LP | 622,882 | $1.7M | 0.0% | +92,070 |
| State Street Corp | 600,528 | $1.6M | 0.0% | +448,800 |
| Northern Trust Corp | 360,744 | $963.2K | 0.0% | +285,532 |
| Vanguard Portfolio Management LLC | 320,795 | $856.5K | 0.0% | New |
| Dimensional Fund Advisors LP | 291,559 | $779.0K | 0.0% | +171,803 |
| Vanguard Fiduciary Trust Co | 291,240 | $777.6K | 0.0% | +92,014 |
| Bank Of America Corp /de/ | 274,781 | $733.7K | 0.0% | −45,435 |
| Boothbay Fund Management, LLC | 273,012 | $728.9K | 0.0% | No change |
| Nomura Holdings Inc | 189,712 | $506.5K | 0.0% | New |
| Goldman Sachs Group Inc | 183,927 | $491.1K | 0.0% | −22,756 |
| Bridgeway Capital Management, LLC | 176,171 | $470.4K | 0.0% | No change |
| Morgan Stanley | 136,763 | $365.2K | 0.0% | −7,821 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Acumen Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAcumen Pharmaceuticals, Inc.1
- CIK0001576885
- Employer ID (EIN)36-41081293
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1210-1220 Washington Street, Suite 210, Newton, MA 024651
- Phone617-344-41901
- Shares outstanding72,317,285 as of Aug 7, 202610
- Public float$45.3M as of Jun 30, 20253
- AuditorErnst & Young LLP, Philadelphia, Pennsylvania PCAOB ID 42; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceMay 15, 20131
- Filings358 in all: 4 (120), 144 (61), 8-K (54), 3 (19), 10-Q (16), CORRESP (8), S-8 (7), SC 13G (7)1
All 36 form types
SC 13G/A (6), UPLOAD (6), 10-K (5), DEF 14A (5), DEFA14A (5), 424B5 (4), ARS (4), EFFECT (4), S-3 (3), DRS/A (2), SC 13D/A (2), SCHEDULE 13D/A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), DRS (1), DRSLTR (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1), SC 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 26, 2026
Quarterly report (10-Q) Aug 12, 2026
Proxy statement (DEF 14A) Apr 23, 2026
Latest 8-K (8-K) Sep 16, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | ABOS | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Acumen Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 72 risks under these headings, as written.3
- Risks Related to our Financial Position and Capital Needs
- We are a clinical-stage biopharmaceutical company with a limited operating history.
- We have no product candidates approved for commercial sale, we have never generated any revenue from product sales and we may never be profitable.
- We will require substantial additional funding to finance our operations, complete the development and commercialization of sabirnetug for AD and evaluate future product candidates, including any Aß oligomer-targeted EBD™ product candidates we may develop pursuant to our collaboration with JCR. If we are unable to raise additional funding when needed, we may be forced to delay, reduce or eliminate our drug development programs or other operations.
- Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included in this Annual Report on Form 10-K.
- The terms of our Loan Agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.
- We are exposed to interest rate risk under our Loan Agreement with K2HV, which could cause our debt service obligations to increase significantly.
- Risks Related to the Development of our Product Candidates
- We are substantially dependent on the success of sabirnetug, our sole product candidate, which will require significant clinical testing before we can seek regulatory approval and potentially launch commercial sales, and which may not be successful in clinical trials, receive regulatory approval or be successfully commercialized, even if approved.
- The FDA granted Fast Track designation for sabirnetug for the treatment of early AD, and we may seek Fast Track designation for other product candidates. Even if received, Fast Track designation may not actually lead to a faster review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
- We have concentrated our research and development efforts on the treatment of AD, a field that has to date seen very limited success in drug development.
- Our approach to the potential treatment of AD is based on a novel therapeutic approach, which exposes us to unforeseen risks.
The other 62 risks
- Nonclinical and clinical drug development involves a lengthy, expensive and uncertain process. The results of nonclinical studies and early clinical trials are not always predictive of future results. Sabirnetug or any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.
- Clinical failure can occur at any stage of clinical development, and we have never submitted a biologics license application, or BLA, or other marketing authorization application, or MAA.
- We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- Adverse side effects, properties or other safety risks associated with sabirnetug or any future product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon further development, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
- We have experienced and may continue to experience delays or difficulties in the enrollment and retention of patients in clinical trials, which could delay or prevent our receipt of necessary regulatory approvals.
- Interim, “topline” and preliminary results from our clinical trials that we announce or publish from time to time may change as more data become available and is subject to audit and verification procedures that could result in material changes in the final data.
- We cannot be certain that sabirnetug or any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market our product candidates.
- We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA, EMA and other comparable foreign regulatory authorities may not accept data from such trials.
- We may not be successful in our efforts to build a pipeline of additional product candidates.
- If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.
- We may develop sabirnetug and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.
- Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
- We face uncertainty regarding potential regulatory developments that may adversely affect our business.
- Risks Related to the Commercialization of Our Product Candidates
- Even if sabirnetug or any other product candidate we may develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- If we are unable to enter into a commercial collaboration or, alternatively, establish internal sales, marketing and distribution capabilities for sabirnetug or any other product candidate, including any Aß oligomer-targeted EBD™ product candidates we may develop pursuant to our collaboration with JCR, that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved.
- The affected populations for sabirnetug or any other product candidate we may develop may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.
- Off-label use or misuse of our products may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product.
- We may pursue Breakthrough Therapy designation by the FDA. This designation may not actually lead to a faster development or regulatory review or approval process, and it does not assure FDA approval of any product candidates we may develop.
- We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more effective than ours.
- Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
- The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these therapies.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
- We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.
- If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could seriously harm our business.
- Risks Related to Our Dependence on Third Parties
- We currently rely on CMOs to supply components of and manufacture sabirnetug. The loss of any of these CMOs or the failure of any of them to meet their obligations to us could affect our ability to develop sabirnetug in a timely manner.
- We intend to rely on CROs and other third parties to conduct, supervise and monitor a significant portion of our research and nonclinical testing and clinical trials for sabirnetug or any future product candidates, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business may be substantially harmed.
- If any of our third-party manufacturers encounter difficulties in production of sabirnetug or any future product candidate we develop, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or, if approved, for commercial sale could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.
- We will likely seek collaborations with third parties for the development and commercialization of sabirnetug or any future product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates, including sabirnetug.
- We may be exposed to a variety of international risks that could materially adversely affect our business.
- If we engage in acquisitions, we will incur a variety of costs and we may never realize the anticipated benefits of such acquisitions.
- Risks Related to Our Intellectual Property
- If we are unable to obtain and maintain sufficient intellectual property protection for sabirnetug and any future product candidates, including any Aß oligomer-targeted EBD™ product candidates, as well as any other proprietary technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidate, and other proprietary technologies if approved, may be adversely affected.
- Patent terms may be inadequate to protect our competitive position on our product candidate for an adequate amount of time.
- If we do not obtain patent term extension for our product candidate our business may be materially harmed.
- If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidate.
- We may not be able to protect our intellectual property rights throughout the world.
- We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through in-licenses.
- Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
- We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
- Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Intellectual property discovered through government funded programs may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
- Risks Related to Legal and Regulatory Compliance Matters
- Our business operations, including our relationships with healthcare providers, such as physicians, third-party payors, patients, other customers or organizations in a position to influence current and future business, are subject, directly or indirectly, to extensive regulation under healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Even if we obtain regulatory approval for sabirnetug or any future product candidates, they will remain subject to ongoing regulatory oversight, which may result in significant additional expense.
- Even if we obtain FDA or EMA approval for any of our product candidates in the United States or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.
- Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations.
- Our business activities may be subject to the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, and similar anti-bribery and anti-corruption laws.
- Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business.
- Our business and operations would suffer in the event of computer system failures, cyberattacks or a deficiency in our cybersecurity or a natural disaster.
- Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.
- Risks Related to Employee Matters and Managing our Growth
- We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.
- We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.
- If we fail to build our finance infrastructure and improve our accounting systems and controls, we may be unable to comply with the financial reporting and internal controls requirements for publicly traded companies.
- Risks Related to Ownership of our Common Stock and our Status as a Public Company
- An active trading market for our common stock may not continue to be developed or sustained.
- The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.
- If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
- Future sales of our common stock in the public market could cause our share price to fall.
- Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.
Legal proceedings
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARJames J. Doherty, President
- 12SEC EDGARMatt Zuga, Chief financial officer
- 13
- 14
- 15SEC EDGAREric Siemers, Chief Medical Officer
- 16SEC EDGARGeorge Golumbeski, Board member
- 17SEC EDGARDerrell Porter, Board member
- 18SEC EDGARKimberlee C. Drapkin, Board member
- 19SEC EDGARJeffrey L. Ives, Board member
- 20SEC EDGARJeffrey Sevigny, Board member
- 21SEC EDGARLaura Stoppel, Board member
- 22SEC EDGARNathan B. Fountain, Board member
- 23SEC EDGARPeter Kolchinsky, Board member
- 24SEC EDGARSean Stalfort, Board member
- 25SEC EDGARDerek M. Meisner, General counsel
- 26SEC EDGARRegulation FD disclosure
- 27
- 28
- 29SEC EDGARShareholder vote
- 30
- 31
- 32
- 33SEC EDGARRegulation FD disclosure
- 34
- 35
- 36
- 37
- 38NasdaqNasdaq calendar
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51